Comparative Pharmacology
Head-to-head clinical analysis: FANAPT versus ZIPRASIDONE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FANAPT versus ZIPRASIDONE MESYLATE.
FANAPT vs ZIPRASIDONE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FANAPT (iloperidone) is an atypical antipsychotic that exhibits high affinity for serotonin 5-HT2A and dopamine D2 receptors, with additional antagonism at alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors. The therapeutic efficacy is primarily attributed to combined 5-HT2A and D2 receptor antagonism.
Ziprasidone mesylate is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also antagonizes 5-HT1D, 5-HT2C, and alpha1-adrenergic receptors, and inhibits serotonin and norepinephrine reuptake.
12-24 mg orally once daily, titrated from 1 mg twice daily on day 1, 2 mg twice daily on day 2, 4 mg twice daily on day 3, 6 mg twice daily on day 4, 8 mg twice daily on day 5, then 10 mg twice daily on day 6 and 7, followed by 12 mg once daily on day 8. Maximum dose: 24 mg/day.
20 mg intramuscularly (IM) as needed, not to exceed 40 mg/day; oral: 20 mg twice daily with food, titrated up to 80 mg twice daily. Maximum: 160 mg/day oral.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 22-30 hours) for the sum of parent drug and active metabolites (P95, P88, and P86); steady-state achieved within 4-5 days.
Terminal elimination half-life is approximately 2.2 hours (range 1.4–3.6 h) for the mesylate salt; clinical context: requires twice-daily dosing.
Renal (approximately 80% as metabolites, <1% as parent drug) and fecal (approximately 20% as metabolites).
Approximately 20% renal, 80% fecal/biliary. Unchanged drug accounts for <1% of renal excretion.
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic